Observational studySleep & breathing = Schlaf & Atmung2025
Evaluation of obstructive sleep apnea syndrome in sarcoidosis patients: a clinical and polysomnographic analysis.
Observational study in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile some studies suggest an elevated risk of obstructive sleep apnea (OSA) in sarcoidosis, comprehensive research remains limited. This study aims to assess the prevalence of OSA among sarcoidosis patients, compare its occurrence with the general population, and evaluate the clinical and polysomnographic features of sarcoidosis patients diagnosed with OSA.
methodsThis prospective observational study identified 150 out of 290 sarcoidosis-diagnosed patients with OSA symptoms. Of these, 52 underwent polysomnography (PSG), and 45 patients with an Apnea-Hypopnea Index (AHI) ≥ 5 events/hour were included. The control group consisted of 48 OSA patients without lung disease history who had previously undergone PSG. Demographic, anthropometric, clinical, and polysomnographic parameters were compared between groups. Respiratory function test results and pulmonary involvement were also analyzed for sarcoidosis patients.
resultsNinety-three patients (45 sarcoidosis, 48 controls) were included. Sarcoidosis patients had a mean age of 50.7 ± 9.5 years, with 68.8% female and 55.5% obese. Pulmonary involvement was observed in 20%, and 62.5% of actively treated patients received corticosteroids. The median AHI and ODI values for sarcoidosis patients were 17.9 and 13.5, respectively. Supine apnea count was significantly higher in sarcoidosis patients (p = 0.003). N3 sleep stage proportion was significantly lower in severe OSA (p = 0.006). Pulmonary involvement increased with OSA severity: 2.2% in mild, 6.6% in moderate, and 11.1% in severe cases.
conclusionOSA is a common comorbidity in sarcoidosis; warranting further investigation to optimize management in this population.
Indexed as
Identifiers
40699258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.